Drug
Camostat Mesylate
Camostat Mesylate is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 50.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
1(25%)
Results Posted
0%(0 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_3
1
25%
Ph phase_1
1
25%
Ph phase_2
2
50%
Phase Distribution
1
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(1)
Terminated(2)
Detailed Status
Completed1
Terminated1
Recruiting1
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
50.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (25.0%)
Phase 22 (50.0%)
Phase 31 (25.0%)
Trials by Status
completed125%
terminated125%
recruiting125%
withdrawn125%
Recent Activity
1 active trials
Showing 4 of 4
recruitingphase_2
Effect Camostat for Kidney Protection in Chronic Kidney Disease
NCT06794593
completedphase_2
Camostat Mesylate for Protein-losing Enteropathy After Fontan Operation
NCT05474664
withdrawnphase_1
The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications
NCT04435015
terminatedphase_3
CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients
NCT04608266
Clinical Trials (4)
Showing 4 of 4 trials
NCT06794593Phase 2
Effect Camostat for Kidney Protection in Chronic Kidney Disease
NCT05474664Phase 2
Camostat Mesylate for Protein-losing Enteropathy After Fontan Operation
NCT04435015Phase 1
The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications
NCT04608266Phase 3
CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4